Trending Topic

23 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Luke G Qin, Michael T Pierce, Rachel C Robbins

The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part of the eye, such as the vitreous or peripheral retina. The clinical taxonomy of uveitis […]

How to Choose the Best Cross-linking Procedure in 2016

Nikki Hafezi, Farhad Hafezi
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Dec 21st 2015 European Ophthalmic Review, 2015;9(2):Epub ahead of print
Select a Section…
1

Abstract

Overview

Ever since cross-linking (CXL) technology was introduced into clinical ophthalmology in 1999, the technique has established itself as a
standard of care in the treatment of corneal ectasia. The original protocol, referred to as the ‘Dresden protocol’, consisted of 30 minutes
of iso-osmolaric riboflavin instillation on a de-epithelialised cornea, followed by irradiation at 365 nm and 3 mW/cm2 for 30 minutes. These
settings correspond to a fluence of 5.4 J/cm2. A large variety of modifications of this original protocol have emerged in the past years: some
of these modifications are backed up by a solid body of research evidence, both clinically and experimentally, whereas other modifications
are based on little to no scientific evidence. Navigating through this ‘sea of new protocols’ is becoming increasingly difficult for the treating
ophthalmologist. The two most important modifications are transepithelial (epi-on) CXL and accelerated CXL. Most interestingly, they seem
to share a final common pathway, which determines efficacy: oxygen dependency.

Keywords

Epi-on, transepithelial, iontophoresis, epi-off, corneal cross-linking, CXL, oxygen

2

Article Information

Disclosure

Nikki Hafezi is Chief Executive Officer of EMAGine SA, Farhad Hafezi is Chief Medical Officer of EMAGine SA, and named co-inventor of PCT/CH 2012/000090
application (UV light source). No funding was received in the publication of this article.

Correspondence

Farhad Hafezi, ELZA Institute, Webereistrasse 2, CH – 8953 Dietikon. E: farhad@hafezi.ch

Access

This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation
and reproduction provided the original author(s) and source are given appropriate credit.

Received

2015-11-24T00:00:00

3

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup